Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT05814666 is registered in ClinicalTrials.gov with Flamingo Therapeutics NV as lead sponsor.

NCT NCT05814666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05814666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Flamingo Therapeutics NV
Phase
Phase 2
Overall status
Terminated
Start date
May 30, 2023
Completion date
August 14, 2025
Enrollment
69 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc